Cargando…
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
BACKGROUND: The vast majority of patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab eventually develop resistance to this agent. There is an unmet need therefore, for identifying biological markers with possible prognostic/predictive value in such patients. The aim o...
Autores principales: | Fountzilas, George, Christodoulou, Christos, Bobos, Mattheos, Kotoula, Vassiliki, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Batistatou, Anna, Pentheroudakis, George, Xiros, Nikolaos, Papaspirou, Irene, Koumarianou, Anna, Papakostas, Pavlos, Bafaloukos, Dimitrios, Skarlos, Dimosthenis V, Kalogeras, Konstantine T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499161/ https://www.ncbi.nlm.nih.gov/pubmed/23092535 http://dx.doi.org/10.1186/1479-5876-10-212 |
Ejemplares similares
-
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016) -
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
por: Koutras, Angelos, et al.
Publicado: (2018) -
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
por: Kostopoulos, Ioannis, et al.
Publicado: (2009) -
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014) -
Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)